Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
May 03, 2024 11:23 ET
|
CG Oncology Inc.
Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024
April 26, 2024 08:00 ET
|
CG Oncology Inc.
CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024
Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2024
April 25, 2024 07:00 ET
|
Morphic Therapeutic
MORF ends 1Q24 with $659 million, cash into 2H27; phase 2b study of MORF-057 in UC continues on target; anticipate GARNET phase 2 in Crohn's to begin 2Q
Enterome to Present Clinical Data on EO2463 in B-cell Lymphoma at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
April 25, 2024 06:00 ET
|
Enterome
PARIS, April 25, 2024 (GLOBE NEWSWIRE) -- Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its...
BriaCell Announces Oral and Poster Presentations at ASCO 2024
April 24, 2024 08:00 ET
|
BriaCell Therapeutics Corp.
Oral presentation by Mayo Clinic Professor and Principal Investigator, Saranya Chumsri, MDTwo poster presentations include Drs. Hurvitz (Fred Hutchinson Cancer Center), Brufsky (UPMC), and...
Diamond Equity Research Releases Update Note on ProPhase Labs Inc. (NASDAQ: PRPH)
April 23, 2024 09:00 ET
|
Diamond Equity Research LLC; ProPhase Labs Inc.
NEW YORK, April 23, 2024 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released an Update Note on ProPhase...
Global Oncology Precision Medicine Market Trends and Forecasts Report 2024: A $364 Billion Industry by 2035 Amidst a Clinical Trials Boom with Over 6,500 Trials
April 23, 2024 04:37 ET
|
Research and Markets
Dublin, April 23, 2024 (GLOBE NEWSWIRE) -- The "Oncology Precision Medicine Market: Industry Trends and Global Forecasts, Till 2035: Distribution by Type of Cancer Targeted, Route of Administration,...
Celularity Abstract “Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials” Accepted at ORS Tendon Conference 2024
April 18, 2024 16:30 ET
|
Celularity Inc.
FLORHAM PARK, N.J., April 18, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative medicine company developing placental-derived allogeneic cell therapies and...
Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual Meeting
April 17, 2024 16:05 ET
|
Vigil Neuroscience, Inc.
- Findings from ILLUMINATE Natural History Study show that MRI and fluid biomarkers are emerging as key measures of ALSP pathophysiology - - Positive interim IGNITE Phase 2 data demonstrating...
AskBio presents 18-month Phase Ib trial results of AB-1005 gene therapy for patients with Parkinson’s disease
April 16, 2024 08:03 ET
|
Asklepios BioPharmaceutical, Inc. (AskBio)
Berlin, Germany, and Research Triangle Park, NC, USA, April 16, 2024 (GLOBE NEWSWIRE) -- Not intended for UK Media AB-1005 (also known as AAV2-GDNF), an investigational gene therapy for the...